Jazz Pharmaceuticals PLC. Daily Stock Analysis

Daily Stock Analysis, JAZZ, Jazz Pharmaceuticals PLC, priceseries

Jazz Pharmaceuticals PLC. Daily Stock Analysis
Stock Information
Open
151.97
Close
153.96
High
159.94
Low
151.30
Previous Close
154.42
Daily Price Gain
-0.46
YTD High
159.94
YTD High Date
Mar 7, 2022
YTD Low
126.14
YTD Low Date
Jan 3, 2022
YTD Price Change
22.95
YTD Gain
17.52%
52 Week High
189.00
52 Week High Date
Jun 15, 2021
52 Week Low
117.64
52 Week Low Date
Nov 30, 2021
52 Week Price Change
-7.45
52 Week Gain
-4.62%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 30. 2016
109.03
Jan 24. 2017
120.38
15 Trading Days
10.41%
Link
LONG
Jan 31. 2017
121.92
Feb 28. 2017
132.09
19 Trading Days
8.34%
Link
LONG
May 30. 2018
168.48
Jun 22. 2018
178.50
17 Trading Days
5.95%
Link
LONG
Nov 8. 2019
130.14
Dec 3. 2019
144.72
16 Trading Days
11.20%
Link
LONG
Aug 26. 2020
124.77
Sep 21. 2020
137.20
17 Trading Days
9.96%
Link
LONG
Dec 22. 2020
151.51
Jan 26. 2021
166.64
22 Trading Days
9.99%
Link
LONG
Jan 6. 2022
132.74
Jan 19. 2022
140.93
8 Trading Days
6.17%
Link
Company Information
Stock Symbol
JAZZ
Exchange
NasdaqGS
Company URL
http://www.jazzpharma.com
Company Phone
353-1-634-7800
CEO
Bruce C. Cozadd
Headquarters
-
Business Address
FIFTH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD, DUBLIN, IRELAND 4
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001232524
About

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products. It has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd on January 18, 2012 and is headquartered in Dublin, Ireland.

Description

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinson's disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading